Non-inferiority of a Commercial Lot of the Pneumococcal Vaccine GSK1024850A Compared to a Clinical Lot.

The purpose of the present study is to demonstrate that the changes in the manufacturing process for the commercial lot of the pneumococcal conjugate vaccine GSK1024850A have no clinical impact and that the immune responses are non-inferior to the immune responses induced by the clinical lot. The study will be conducted in Singapore and Malaysia.

本研究旨在证实，肺炎球菌结合疫苗（pneumococcal conjugate vaccine）GSK1024850A商业批次的生产工艺变更无临床影响，且其诱导的免疫应答不劣于临床批次诱导的免疫应答。本研究将在新加坡与马来西亚开展。